Cargando…

Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer

INTRODUCTION AND OBJECTIVES: PD-L1 and B7-H3 have been found to be overexpressed in urothelial carcinoma (UC) of the urinary bladder. Recent studies have also demonstrated that B7-H3 and PD-L1 can promote resistance to platinum-based drugs but the predictive value of B7-H3 expression in patients tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmoud, Ahmed M., Frank, Igor, Orme, Jacob J., Lavoie, Roxane R., Thapa, Prabin, Costello, Brian A., Cheville, John C., Gupta, Sounak, Dong, Haidong, Lucien, Fabrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233321/ https://www.ncbi.nlm.nih.gov/pubmed/35751046 http://dx.doi.org/10.1186/s12894-022-01044-1

Ejemplares similares

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities
por: Mahmoud, Ahmed M, et al.
Publicado: (2023)

Targeting endosomal pH for cancer chemotherapy
por: Lucien, Fabrice, et al.
Publicado: (2018)

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
por: Davidson, Tara M, et al.
Publicado: (2022)

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
por: Orme, Jacob J., et al.
Publicado: (2020)

The anti-B7-H3 blocking antibody MJ18 does not recognize B7-H3 in murine tumor models
por: Nammor, Talah, et al.
Publicado: (2023)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion
por: Lavoie, Roxane R., et al.
Publicado: (2021)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
por: Eckel‐Passow, Jeanette E., et al.
Publicado: (2019)

Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy
por: Sui, Wilson, et al.
Publicado: (2017)

Emerging Roles of Urine-Derived Components for the Management of Bladder Cancer: One Man’s Trash Is Another Man’s Treasure
por: Minkler, Sarah, et al.
Publicado: (2021)

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
por: Yan, Sen, et al.
Publicado: (2022)

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
por: Liu, Chunnan, et al.
Publicado: (2022)

Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse
por: Zattoni, Fabio, et al.
Publicado: (2018)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
por: Eldefrawy, Ahmed, et al.
Publicado: (2012)

Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer
por: Sawasdee, Anupong, et al.
Publicado: (2022)

Adjuvant chemotherapy
por: Glimelius, B.
Publicado: (2013)

Bladder carcinosarcoma treated by cystectomy and adjuvant chemotherapy with good outcomes: a case report
por: Kouhen, Fadila, et al.
Publicado: (2023)

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
por: Sun, Jong-Mu, et al.
Publicado: (2012)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
por: Wezel, Felix, et al.
Publicado: (2017)

Adjuvant chemotherapy versus observation after radical cystectomy in patients with node-positive bladder cancer
por: Pak, Sahyun, et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Chemotherapy for Variant Histology Bladder Cancers: A Systematic Review and Meta-Analysis
por: Zhu, Ziwei, et al.
Publicado: (2022)

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer
por: Olah, Csilla, et al.
Publicado: (2022)

Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer
por: Liu, J., et al.
Publicado: (2023)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer
por: Dykstra, Mark A., et al.
Publicado: (2017)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2015)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2016)

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018)

Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis
por: Cai, Zhiyong, et al.
Publicado: (2021)

Accelerating Cancer Histopathology Workflows with Chemical Imaging and Machine Learning
por: Falahkheirkhah, Kianoush, et al.
Publicado: (2023)

Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
por: Yazaki, Shu, et al.
Publicado: (2022)

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy
por: Gu, Yun, et al.
Publicado: (2022)

Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity
por: Lucien, Fabrice, et al.
Publicado: (2022)

Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer
por: Qian, Hao, et al.
Publicado: (2021)

Adjuvant chemotherapy for colorectal cancer
por: Maughan, T S
Publicado: (2001)

What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
por: Keck, Bastian, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4gd2pmibnqlc3d06kgo7t3alqr